21 related articles for article (PubMed ID: 31098998)
1. Bio-Responsive Macromolecular Drug and Small-Molecular Drug Conjugates: Nanoparticulate Prodrugs for Tumor Microenvironment Heterogeneity Management and Therapeutic Response Enhancement.
Li Y; Liang X; Shen C; Deng K; Zeng Z; Guo B; Xu X
Small; 2023 Sep; 19(39):e2301656. PubMed ID: 37144435
[TBL] [Abstract][Full Text] [Related]
2. A Tumor-Specific Cascade-Activating Smart Prodrug System for Enhanced Targeted Therapy.
Wang Q; Jin D; Liu C; Shi L; Li T
Small; 2024 Jun; 20(24):e2309482. PubMed ID: 38150668
[TBL] [Abstract][Full Text] [Related]
3. From prodrug to pro-prodrug: hypoxia-sensitive antibody-drug conjugates.
Wang Y; Xiao D; Li J; Fan S; Xie F; Zhong W; Zhou X; Li S
Signal Transduct Target Ther; 2022 Jan; 7(1):20. PubMed ID: 35058439
[No Abstract] [Full Text] [Related]
4. Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.
Salzano G; Costa DF; Sarisozen C; Luther E; Mattheolabakis G; Dhargalkar PP; Torchilin VP
Small; 2016 Sep; 12(35):4837-4848. PubMed ID: 27432595
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of paclitaxel and doxorubicin using mixed micelles based on the redox sensitive prodrugs.
Yang M; Ding H; Zhu Y; Ge Y; Li L
Colloids Surf B Biointerfaces; 2019 Mar; 175():126-135. PubMed ID: 30529818
[TBL] [Abstract][Full Text] [Related]
6. A macromolecular prodrug strategy for combinatorial drug delivery.
Li NN; Lin J; Gao D; Zhang LM
J Colloid Interface Sci; 2014 Mar; 417():301-9. PubMed ID: 24407691
[TBL] [Abstract][Full Text] [Related]
7. Self-assemblies of pH-activatable PEGylated multiarm poly(lactic acid-co-glycolic acid)-doxorubicin prodrugs with improved long-term antitumor efficacies.
Ding J; Li D; Zhuang X; Chen X
Macromol Biosci; 2013 Oct; 13(10):1300-7. PubMed ID: 23852836
[TBL] [Abstract][Full Text] [Related]
8. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
[TBL] [Abstract][Full Text] [Related]
9. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
10. Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.
Sritharan S; Guha S; Hazarika S; Sivalingam N
Apoptosis; 2022 Oct; 27(9-10):622-646. PubMed ID: 35716277
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Doxorubicin and miRNA Stimuli-Sensitive Conjugates for Combination Therapy.
Costa DF; Sarisozen C; Torchilin VP
Methods Mol Biol; 2019; 1974():99-109. PubMed ID: 31098998
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
